Global Hormone Refractory Prostate Cancer (HRPCA) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hormone Refractory Prostate Cancer (HRPCA) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Hormone Refractory Prostate Cancer (HRPCA) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hormone Refractory Prostate Cancer (HRPCA) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Ambulatory Surgical Centers are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Hormone Refractory Prostate Cancer (HRPCA) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Hormone Refractory Prostate Cancer (HRPCA) key companies include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG are top 3 players and held % share in total in 2022.
Hormone Refractory Prostate Cancer (HRPCA) can be divided into Cytotoxic Agents, Anti-Androgens, Vaccines and Radio-Pharmaceuticals, etc. Cytotoxic Agents is the mainstream product in the market, accounting for % share globally in 2022.
Hormone Refractory Prostate Cancer (HRPCA) is widely used in various fields, such as Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others, etc. Hospitals provides greatest supports to the Hormone Refractory Prostate Cancer (HRPCA) industry development. In 2022, global % share of Hormone Refractory Prostate Cancer (HRPCA) went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hormone Refractory Prostate Cancer (HRPCA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hormone Refractory Prostate Cancer (HRPCA) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Hormone Refractory Prostate Cancer (HRPCA) introduction, etc. Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Hormone Refractory Prostate Cancer (HRPCA) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Hormone Refractory Prostate Cancer (HRPCA) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hormone Refractory Prostate Cancer (HRPCA) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Ambulatory Surgical Centers are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Hormone Refractory Prostate Cancer (HRPCA) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Hormone Refractory Prostate Cancer (HRPCA) key companies include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG are top 3 players and held % share in total in 2022.
Hormone Refractory Prostate Cancer (HRPCA) can be divided into Cytotoxic Agents, Anti-Androgens, Vaccines and Radio-Pharmaceuticals, etc. Cytotoxic Agents is the mainstream product in the market, accounting for % share globally in 2022.
Hormone Refractory Prostate Cancer (HRPCA) is widely used in various fields, such as Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others, etc. Hospitals provides greatest supports to the Hormone Refractory Prostate Cancer (HRPCA) industry development. In 2022, global % share of Hormone Refractory Prostate Cancer (HRPCA) went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hormone Refractory Prostate Cancer (HRPCA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hormone Refractory Prostate Cancer (HRPCA) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Hormone Refractory Prostate Cancer (HRPCA) introduction, etc. Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Hormone Refractory Prostate Cancer (HRPCA) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices